Endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) cytology/biopsy is currently performed at many institutions and has become a routine procedure for pathologic diagnosis of pancreatic lesions. Although endoscopic ultrasound scanning began in the early 1980s [1], it has gained widespread popularity since the introduction of fine needle aspiration cytology/biopsy devices, which allow guided biopsies of target lesions visualized by endoscopic ultrasound [2]. Before the era of EUS-FNA, it was difficult to target pancreatic lesions due to limited accessibility by percutaneous needle biopsies. Hence, pathologists could rarely encounter cytology and/or biopsy material from pancreatic lesions. With the increasing popularity of EUS-FNA procedures, interpretation of EUS-FNA cytology/biopsy material has become an almost inevitable part of routine practice for pathologic diagnosis of various pancreatic lesions. A main concern of pancreatic EUS-FNA specimen interpretation is the limited amount of aspirated material. Compared to aspirated material from superficial organs, such as the thyroid, breast, or uterine cervix, EUS-FNA from pancreatic lesions provides aspirates with relatively limited cellularity that may seem inadequate to less experienced pathologists. However, EUS-FNA inevitably results in lower cellularity compared to aspirates from other superficial organs. To make an appropriate diagnosis, pathologists should consider the clinical impression, especially radiologic and/or EUS findings; otherwise, many EUS-FNA specimens may be interpreted as "inadequate specimen". It is occasionally necessary to deem the sample "inadequate", "atypical", or of "uncertain malignant potential", which are diagnostically less useful to clinicians, but necessary. The use of these indeterminate categories will be reduced with expertise and correlation of cytologic